Mark J. Smyth

118.6k total citations · 40 hit papers
595 papers, 81.6k citations indexed

About

Mark J. Smyth is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mark J. Smyth has authored 595 papers receiving a total of 81.6k indexed citations (citations by other indexed papers that have themselves been cited), including 452 papers in Immunology, 265 papers in Oncology and 128 papers in Molecular Biology. Recurrent topics in Mark J. Smyth's work include Immune Cell Function and Interaction (339 papers), T-cell and B-cell Immunology (173 papers) and Immunotherapy and Immune Responses (162 papers). Mark J. Smyth is often cited by papers focused on Immune Cell Function and Interaction (339 papers), T-cell and B-cell Immunology (173 papers) and Immunotherapy and Immune Responses (162 papers). Mark J. Smyth collaborates with scholars based in Australia, United States and Japan. Mark J. Smyth's co-authors include Robert D. Schreiber, Michele W.L. Teng, Joseph A. Trapani, Lloyd J. Old, Dale I. Godfrey, Yoshihiro Hayakawa, Hideo Yagita∥, Kazuyoshi Takeda, Shin Foong Ngiow and Jeremy B. Swann and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark J. Smyth

589 papers receiving 80.5k citations

Hit Papers

Cancer Immunoediting: Int... 2000 2026 2008 2017 2011 2011 2018 2015 2014 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
    2011 4.6k citations Robert D. Schreiber, Mark J. Smyth et al. profile →
  2. Natural Innate and Adaptive Immunity to Cancer
    2011 1.5k citations Matthew D. Vesely, Michael H. Kershaw et al. profile →
  3. Cancer immunoediting and resistance to T cell-based immunotherapy
    2018 1.3k citations Michele W.L. Teng, Mark J. Smyth et al. profile →
  4. Classifying Cancers Based on T-cell Infiltration and PD-L1
    2015 1.1k citations Michele W.L. Teng, Shin Foong Ngiow et al. Cancer Research profile →
  5. New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape
    2014 1.1k citations Deepak Mittal, Robert D. Schreiber et al. profile →
  6. Immune surveillance of tumors
    2007 1.1k citations Jeremy B. Swann, Mark J. Smyth profile →
  7. Adaptive immunity maintains occult cancer in an equilibrium state
    2007 1.0k citations Jeremy B. Swann, Nadeen Zerafa et al. profile →
  8. Translational biology of osteosarcoma
    2014 978 citations Maya Kansara, Michele W.L. Teng et al. profile →
  9. Type I interferons in anticancer immunity
    2015 964 citations Laurence Zitvogel, Mark J. Smyth et al. profile →
  10. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    2014 956 citations Sherene Loi, Mark J. Smyth et al. profile →
  11. NKT cells: what's in a name?
    2004 955 citations Dale I. Godfrey, Mark J. Smyth et al. profile →
  12. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    2012 932 citations Matthew D. Vesely, Mark J. Smyth et al. profile →
  13. Functional significance of the perforin/granzyme cell death pathway
    2002 929 citations Joseph A. Trapani, Mark J. Smyth profile →
  14. Targeting natural killer cells in cancer immunotherapy
    2016 832 citations Nicholas D. Huntington, Mark J. Smyth et al. profile →
  15. Combination cancer immunotherapies tailored to the tumour microenvironment
    2015 738 citations Mark J. Smyth, Shin Foong Ngiow et al. profile →
  16. The TRAIL apoptotic pathway in cancer onset, progression and therapy
    2008 712 citations Ricky W. Johnstone, Mark J. Smyth et al. profile →
  17. NKT cells: facts, functions and fallacies
    2000 704 citations Dale I. Godfrey, Mark J. Smyth et al. profile →
  18. Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
    2013 681 citations Laurence Zitvogel, Mark J. Smyth et al. profile →
  19. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
    2015 639 citations Michele W.L. Teng, Mark J. Smyth et al. profile →
  20. Clinical relevance of host immunity in breast cancer: from TILs to the clinic
    2015 638 citations Phillip K. Darcy, Mark J. Smyth et al. profile →
  21. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
    2000 628 citations Mark J. Smyth, Erika Cretney et al. The Journal of Experimental Medicine profile →
  22. Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
    2006 620 citations Mark J. Smyth, Robert D. Schreiber et al. profile →
  23. Targeting immunosuppressive adenosine in cancer
    2017 608 citations Arabella Young, Michele W.L. Teng et al. profile →
  24. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses
    2010 608 citations Michelle A. Linterman, Laura Beaton et al. The Journal of Experimental Medicine profile →
  25. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell–intrinsic mechanism
    2010 599 citations Dimitra Zotos, Jonathan M. Coquet et al. The Journal of Experimental Medicine profile →
  26. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
    2001 595 citations Kazuyoshi Takeda, Yoshihiro Hayakawa et al. profile →
  27. New aspects of natural-killer-cell surveillance and therapy of cancer
    2002 589 citations Mark J. Smyth, Yoshihiro Hayakawa et al. profile →
  28. A fresh look at tumor immunosurveillance and immunotherapy
    2001 585 citations Mark J. Smyth, Dale I. Godfrey et al. profile →
  29. CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity
    2006 582 citations Yoshihiro Hayakawa, Mark J. Smyth profile →
  30. Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
    2013 571 citations Liza B. John, Christel Devaud et al. profile →
  31. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
    2016 569 citations Shin Foong Ngiow, Kazuyoshi Takeda et al. Cancer Discovery profile →
  32. Control of Metastasis by NK Cells
    2017 548 citations Mark J. Smyth et al. profile →
  33. Activation of NK cell cytotoxicity
    2004 514 citations Mark J. Smyth, Erika Cretney et al. profile →
  34. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
    2016 493 citations Nicholas D. Huntington, Mark J. Smyth et al. profile →
  35. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
    2010 479 citations John Stagg, Upulie Divisekera et al. Proceedings of the National Academy of Sciences profile →
  36. Resistance to PD1/PDL1 checkpoint inhibition
    2016 429 citations Georgina V. Long, Richard A. Scolyer et al. profile →
  37. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
    2013 387 citations Sherene Loi, Benjamin Haibe‐Kains et al. Proceedings of the National Academy of Sciences profile →
  38. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
    2019 379 citations Mark J. Smyth et al. profile →
  39. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
    2020 364 citations Tobias Bald, Mark J. Smyth et al. profile →
  40. ATP and cancer immunosurveillance
    2021 160 citations Mark J. Smyth et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark J. Smyth 52.9k 37.6k 20.2k 6.5k 5.5k 595 81.6k
Laurence Zitvogel 42.4k 0.8× 31.3k 0.8× 31.7k 1.6× 10.1k 1.5× 6.1k 1.1× 492 79.1k
Robert D. Schreiber 48.3k 0.9× 33.6k 0.9× 20.7k 1.0× 7.5k 1.1× 8.7k 1.6× 385 79.6k
Hideo Yagita∥ 43.5k 0.8× 21.7k 0.6× 18.2k 0.9× 6.4k 1.0× 5.2k 0.9× 912 67.3k
Gordon J. Freeman 54.1k 1.0× 38.6k 1.0× 14.7k 0.7× 5.2k 0.8× 6.8k 1.2× 419 82.7k
Michael T. Lotze 26.0k 0.5× 17.2k 0.5× 20.4k 1.0× 6.6k 1.0× 8.4k 1.5× 504 57.5k
Arlene H. Sharpe 47.7k 0.9× 28.8k 0.8× 16.3k 0.8× 3.3k 0.5× 5.9k 1.1× 408 75.8k
Ira Pastan 20.3k 0.4× 30.0k 0.8× 45.5k 2.3× 3.7k 0.6× 3.8k 0.7× 1.2k 90.1k
Vijay K. Kuchroo 59.0k 1.1× 20.6k 0.5× 13.2k 0.7× 2.6k 0.4× 5.2k 0.9× 426 79.1k
Drew M. Pardoll 46.7k 0.9× 45.0k 1.2× 23.5k 1.2× 6.7k 1.0× 5.7k 1.0× 403 83.2k
Tak W. Mak 34.0k 0.6× 22.6k 0.6× 49.6k 2.5× 17.0k 2.6× 7.3k 1.3× 710 96.1k

Countries citing papers authored by Mark J. Smyth

Since Specialization
Citations

This map shows the geographic impact of Mark J. Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Smyth more than expected).

Fields of papers citing papers by Mark J. Smyth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Smyth. The network helps show where Mark J. Smyth may publish in the future.

Co-authorship network of co-authors of Mark J. Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Smyth. A scholar is included among the top collaborators of Mark J. Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Smyth. Mark J. Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kansara, Maya, Puiyi Pang, Aurélie Dutour, et al.. (2019). Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery. 9(11). 1511–1519. 35 indexed citations
2.
3.
Vidacs, Eva, Stephin J. Vervoort, Jason Li, et al.. (2017). HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research. 77(10). 2594–2606. 25 indexed citations
4.
Young, Arabella, Shin Foong Ngiow, Ann‐Marie Patch, et al.. (2017). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Research. 78(4). 1003–1016. 296 indexed citations
5.
Zhao, Yang, Ka Ka Ting, Jia Li, et al.. (2017). Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell–Mediated Immunotherapy. Cancer Research. 77(16). 4434–4447. 50 indexed citations
6.
Young, Arabella, Shin Foong Ngiow, Jason Madore, et al.. (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research. 77(17). 4684–4696. 76 indexed citations
7.
Mittal, Deepak, Debottam Sinha, Deborah S. Barkauskas, et al.. (2016). Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Research. 76(15). 4372–4382. 142 indexed citations
8.
West, Alison C., Stephen R. Mattarollo, Jake Shortt, et al.. (2013). An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. Cancer Research. 73(24). 7265–7276. 117 indexed citations
9.
Stagg, John, Paul A. Beavis, Upulie Divisekera, et al.. (2012). CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research. 72(9). 2190–2196. 174 indexed citations
10.
John, Liza B., Jacqueline K. Flynn, Alison C. West, et al.. (2012). Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research. 72(7). 1651–1660. 92 indexed citations
11.
Verbrugge, Inge, Jim Hagekyriakou, Leslie L. Sharp, et al.. (2012). Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research. 72(13). 3163–3174. 222 indexed citations
12.
Teng, Michele W.L., Matthew D. Vesely, Helene Duret, et al.. (2012). Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research. 72(16). 3987–3996. 88 indexed citations
13.
Mattarollo, Stephen R., Sherene Loi, Helene Duret, et al.. (2011). Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Research. 71(14). 4809–4820. 256 indexed citations
14.
Teng, Michele W.L., Shin Foong Ngiow, Bianca von Scheidt, et al.. (2010). Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth. Cancer Research. 70(20). 7800–7809. 149 indexed citations
15.
Linterman, Michelle A., Laura Beaton, Di Yu, et al.. (2010). IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. The Journal of Experimental Medicine. 207(2). 353–363. 608 indexed citations breakdown →
16.
Zotos, Dimitra, Jonathan M. Coquet, Yang Zhang, et al.. (2010). IL-21 regulates germinal center B cell differentiation and proliferation through a B cell–intrinsic mechanism. The Journal of Experimental Medicine. 207(2). 365–378. 599 indexed citations breakdown →
17.
Swann, Jeremy B., Matthew D. Vesely, Anabel Silva, et al.. (2008). Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences. 105(2). 652–656. 244 indexed citations
18.
Teng, Michele W.L., Jennifer A. Westwood, Phillip K. Darcy, et al.. (2007). Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice. Cancer Research. 67(15). 7495–7504. 55 indexed citations
19.
Smyth, Mark J., Jeremy B. Swann, Erika Cretney, et al.. (2005). NKG2D function protects the host from tumor initiation. The Journal of Experimental Medicine. 202(5). 583–588. 261 indexed citations
20.
Takeda, Kazuyoshi, Noriko Yamaguchi, Hisaya Akiba, et al.. (2004). Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy. The Journal of Experimental Medicine. 199(4). 437–448. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurence Zitvogel Breakdown of academic impact, for papers by Robert D. Schreiber Breakdown of academic impact, for papers by Hideo Yagita∥ Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Michael T. Lotze Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Ira Pastan Breakdown of academic impact, for papers by Vijay K. Kuchroo Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Tak W. Mak
Rankless by CCL
2026